This solicitation closed on June 3, 2026
View current Department of Defense opportunities →Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
AI Overview
This RFP seeks development of small-molecule antifungal compounds effective against resistant fungi like Candida auris and Aspergillus species. The goal is to address rising fungal infection rates and hospitalizations by creating safer, broad-spectrum alternatives to current treatments limited by toxicity and drug resistance.
This summary is AI-generated from the official solicitation.
Key Details
Official Description
Fungal infections represent a growing global health challenge, particularly among immuno-compromised individuals. Invasive fungal infections caused by pathogens such as Candida species, Aspergillus species, Fusarium species, and Mucor species are associated with high morbidity and mortality rates. Fungal infections are associated with 130k hospitalizations, 13 million outpatient visits, and result in a financial burden of $19 billion on the civilian health care sector. Fungal wound infections in...
Change History
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Opportunity DHA26BZ01-DV005 no longer available
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
No changes detected. The previous and updated Q&A sections are identical. All three questions and answers remain the same.
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
**New Q&A Added:** Q1 (David Larwood) clarifies pathogen coverage requirements: Asks whether nM MICs must cover all isolates/all four pathogens, and whether in vivo combination therapy data with standard of care is acceptable. *Answer pending.* Previously answered Q2 (Ravi) and Q3 (skin organoid models) remain unchanged with their original responses.
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
The temperature range for stability testing in austere conditions was narrowed from -55 to 125°C to -32 to 49°C, reducing the extremity of environmental conditions required for product evaluation.
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
This content addresses Phase I/II requirements for antifungal compound development, clarifying acceptability of compounds without standardized breakpoints, alternative efficacy data, cytotoxicity documentation methods, and flexibility in using multiple skin organoid models for testing.
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Status changed from Pre-Release to Open
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Content updated: phase_1_description
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Close Date changed from 2026-04-22 to 2026-06-03
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Open Date changed from 2026-03-25 to 2026-05-06
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Status changed from Removed to Pre-Release
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Opportunity DHA26BZ01-DV005 no longer available
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
New opportunity: Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Similar Opportunities
Get Alerts for Opportunities Like This
RallyProp monitors thousands of funding sources and sends instant alerts when opportunities match your technology and capabilities.
Start Free Trial